Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 53, Issue 2, 2012, Pages 218-224

  Lanasa, Mark C ^a   Davis, Patricia H ^a   Datto, Michael ^a   Li, Zhiguo ^a   Gockerman, Jon P ^a   Moore, Joseph O ^a   Decastro, Carlos M ^a   Friedman, Daphne R ^a   Diehl, Louis F ^a   Rehder, Catherine ^a   Cook, Harry ^b   Daugherty, F Joseph ^b   Matta, Karen M B ^a   Weinberg, J Brice ^a,c   Rizzieri, David ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Eleos Inc   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

Author keywords

Chemotherapeutic approaches; Drug resistance; Lymphoid leukemia

Indexed keywords

CENERSEN; CYCLOPHOSPHAMIDE; FLUDARABINE; PROTEIN P53; RITUXIMAB;

ADULT; AGED; ALLERGY; ANEMIA; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONSTIPATION; DIZZINESS; DRUG EFFECT; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENE MUTATION; HEART DISEASE; HEMOLYTIC ANEMIA; HEMORRHAGIC CYSTITIS; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HUMAN; HYPERGLYCEMIA; INFECTION; LEUKOPENIA; LIVER FAILURE; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN DISEASE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUTATION; OLIGONUCLEOTIDES; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; VIDARABINE;

EID: 84862908172     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.610012     Document Type: Article

References (40)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804-815.
2. Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet 2008;371:1017-1029. (Pubitemid 351389535)
3. F ais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated anDunmutated antigen receptors. J Clin Invest 1998;102:1515-1525. (Pubitemid 28492218)
4. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-1847. (Pubitemid 29430399)
5. H amblin TJ, Davis Z, Gardiner A, et al. UnmutateDig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-1854. (Pubitemid 29430400)
6. C respo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764-1775. (Pubitemid 36514707)
7. Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifi es a chronic lymphocytic leukemia subtype with unmutateDimmunoglobulin genes, inferior clinical outcome, and distinct gene expression profi le. Blood 2003;101:4944-4951. (Pubitemid 36857758)
8. R assenti LZ, Jain S, Keating MJ, et al. Relative value of ZAP-70, CD38, anDimmunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 2008;112:1923-1930.
9. Dohner H, Stilgenbauer S, James MR, et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement anDinferior prognosis. Blood 1997;89:2516-2522. (Pubitemid 27143300)
10. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-1916. (Pubitemid 32064784)
11. Zenz T, Krober A, Scherer K, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008;112:3322-3329.
12. Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010;28:4473-4479.
13. Krober A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002;100:1410-1416. (Pubitemid 34864299)
14. Rosenwald A, Chuang EY, Davis RE, et al. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood 2004;104:1428-1434. (Pubitemid 39166521)
15. Zenz T, Habe S, Denzel T, et al. Detailed analysis of p53 pathway defects in fl udarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 2009;114:2589-2597.
16. Dicker F, Herholz H, Schnittger S, et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression anDis highly correlated with a complex aberrant karyotype. Leukemia 2009;23:117-124.
17. Rossi D, Cerri M, Deambrogi C, et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res 2009;15:995-1004.
18. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009;9:701-713.
19. Dicker F, Kater AP, Prada CE, et al. CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53. Blood 2006;108:3450-3457.
20. Di Como CJ, Gaiddon C, Prives C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol 1999;19:1438-1449. (Pubitemid 29046885)
21. Strano S, Munarriz E, Rossi M, et al. Physical and functional interaction between p53 mutants and diff erent isoforms of p73. J Biol Chem 2000;275:29503-29512. (Pubitemid 32043826)
22. Girnita L, Girnita A, Brodin B, et al. IncreaseDexpression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functionaLimpact. Cancer Res 2000;60:5278-5283.
23. Lee YI, Han YJ, Lee SY, et al. Activation of insulin-like growth factor II signaling by mutant type p53: physiologicaLimplications for potentiation of IGF-II signaling by p53 mutant 249. Mol Cell Endocrinol 2003;203:51-63. (Pubitemid 36627588)
24. Sharp JG, Bishop MR, Copple B, et al. Oligonucleotide enhanced cytotoxicity of idarubicin for lymphoma cells. Leuk Lymphoma 2001;42:417-427. (Pubitemid 32725598)
25. Bayever E, Haines KM, Iversen PL, et al. Selective cytotoxicity to human leukemic myeloblasts produced by oligodeoxyribonucleotide phosphorothioates complementary to p53 nucleotide sequences. Leuk Lymphoma 1994;12:223-231. (Pubitemid 24077171)
26. Bishop MR, Iversen PL, Bayever E, et al. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J Clin Oncol 1996;14:1320-1326. (Pubitemid 26105542)
27. Tam CS, O'B rien S, Wierda W, et al. Long-term results of the fl udarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112: 975-980.
28. Keating MJ, O ' Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fl udarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079-4088. (Pubitemid 46211313)
29. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fl udarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164-1174.
30. Wierda W, O ' Brien S, Wen S, et al. Chemoimmunotherapy with fl udarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005;23: 4070-4078. (Pubitemid 46211312)
31. Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fl udarabine and cyclophosphamide prolongs progression-free survival compared with fl udarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010;28:1756-1765.
32. Badoux XC, Keating MJ, Wang X, et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly Effective treatment for relapsed patients with CLL. Blood 2011;117:3016-3024.
33. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-4997. (Pubitemid 26189840)
34. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446-5456.
35. Hornik K. R FAQ. 2011. Available from: http://CRAN.R-project. org/doc/FAQ/R-FAQ.html
36. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-234.
37. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fl udarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28:1749-1755.
38. Stilgenbauer S, Zenz T, Winkler D, et al. Subcutaneous alemtuzumab in fl udarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009;27:3994-4001.
39. Zenz T, Mertens D, Kuppers R, et al. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010; 10:37-50.
40. Keating MJ, O ' Brien S, Kontoyiannis D, et al. Results of fi rst salvage therapy for patients refractory to a fl udarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002;43:1755-1762. (Pubitemid 34874007)